The clinical-stage developer of RNAi therapies is being added to the S&P 600 index.
News & Analysis: Arrowhead Pharmaceuticals
ARWR earnings call for the period ending March 31, 2019.
Investors cheered the news in a fiscal first-quarter 2019 earnings report.
The company announced fiscal first-quarter 2019 financial results and provided an update for the year ahead.
ARWR earnings call for the period ending December 31, 2018.
A reversal of fortunes made last year one for the record books.
The company updated investors on its financial performance, and on its progress developing RNAi therapies.
ARWR earnings call for the period ending September 30, 2018.
The company announced two late-breaking poster presentations at an important industry meeting -- and impressed with early-stage data.
The company de-risked the development of its potential blockbuster hepatitis B drug for a cool $250 million. Investors thought the price was too low.